Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society by Cuchel, M et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
REVIEW
Clinical update
Homozygous familial hypercholesterolaemia: new
insights and guidance for clinicians to improve
detection and clinical management. A position
paper from the Consensus Panel on Familial
Hypercholesterolaemia of the European
Atherosclerosis Society
Marina Cuchel*, Eric Bruckert, Henry N. Ginsberg, Frederick J. Raal, Raul D. Santos,
Robert A. Hegele, Jan Albert Kuivenhoven, Børge G. Nordestgaard,
Olivier S. Descamps, Elisabeth Steinhagen-Thiessen, Anne Tybjærg-Hansen,
Gerald F. Watts, Maurizio Averna, Catherine Boileau, JanBore´n,AlbericoL.Catapano,
Joep C. Defesche, G. Kees Hovingh,SteveE.Humphries, Petri T. Kovanen, Luis Masana,
Pa¨ivi Pajukanta, Klaus G. Parhofer, Kausik K. Ray, Anton F. H. Stalenhoef, Erik Stroes,
Marja-Riitta Taskinen, Albert Wiegman, Olov Wiklund, and M. John Chapman,
for the European Atherosclerosis Society Consensus Panel on Familial
Hypercholesterolaemia†
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 8039 Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
Received 13 March 2014; revised 19 May 2014; accepted 13 June 2014
Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly ele-
vated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic car-
diovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of
HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the
European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance
for the recognition and management of HoFH.
Methods and
results
Early diagnosis ofHoFHandprompt initiationof diet and lipid-lowering therapy are critical. Genetic testingmayprovide a
definitive diagnosis, but if unavailable, markedly elevated LDL-C levels together with cutaneous or tendon xanthomas
before 10 years, or untreated elevated LDL-C levels consistent with heterozygous FH in both parents, are suggestive
of HoFH.We recommend that patients with suspected HoFH are promptly referred to specialist centres for a compre-
hensiveACVDevaluation and clinicalmanagement. Lifestyle intervention andmaximal statin therapy are themainstays of
treatment, ideally started in the first year of life or at an initial diagnosis, often with ezetimibe and other lipid-modifying
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therapy. As patients rarely achieve LDL-C targets, adjunctive lipoprotein apheresis is recommended where available,
preferably started by age 5 and no later than 8 years. The number of therapeutic approaches has increased following
approval of lomitapide and mipomersen for HoFH. Given the severity of ACVD, we recommend regular follow-up,
including Doppler echocardiographic evaluation of the heart and aorta annually, stress testing and, if available, computed
tomography coronary angiography every 5 years, or less if deemed necessary.
Conclusion This EAS Consensus Panel highlights the need for early identification of HoFH patients, prompt referral to specialized
centres, and early initiation of appropriate treatment. These recommendations offer guidance for a wide spectrum of
clinicians who are often the first to identify patients with suspected HoFH.
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Introduction
Homozygous familial hypercholesterolaemia (HoFH) is a rare and
life-threatening disease originally characterized clinically by plasma
cholesterol levels .13 mmol/L (.500 mg/dL), extensive xantho-
mas, and marked premature and progressive atherosclerotic car-
diovascular disease (ACVD). Studies in cultured fibroblasts from
these patients showed a severe defect in the ability to bind and
internalize LDL particles, subsequently shown to be caused by
mutations in both alleles of the gene encoding the LDL receptor
(LDLR).1 Recent genetic insights, however, indicate that mutations
in alleles of other genes, including APOB, PCSK9, and LDLRAP1, may
be present in some individuals with HoFH.
Untreated, most patients with markedly elevated LDL-C levels
develop overt atherosclerosis before the age of 20 years, and gener-
ally do not survive past 30 years.1 Thus, the primary goals of manage-
ment arepreventionofACVDbyearly and comprehensivecontrolof
hypercholesterolaemia, and early detection of complications, with
specific focus on ostial occlusion and aortic stenosis.2 Unfortunately,
HoFH is typically diagnosed when considerable coronary athero-
sclerosis has already developed, emphasizing the need for optimiza-
tion of treatment in childhood.
Recent advances have highlighted the (i) prevalence and (ii) het-
erogeneity of the genetic defects underlying HoFH and its clinical
phenotype, which are both more pronounced than originally
believed. Therefore, this Consensus Panel on Familial Hypercholes-
terolaemia of the European Atherosclerosis Society (EAS) critically
reviewed current and emerging datawith the aim of providing clinical
guidance for the recognition and management of HoFH patients.
These recommendations are directed not only to cardiologists and
lipid specialists, but also to a wide spectrum of clinicians, including
primary care physicians, paediatricians, dermatologists, and endocri-
nologists, who are often the first to see and hopefully refer these
patients. These recommendations will also be a useful reference
when decisions are made about provision of healthcare for HoFH.
Prevalence of clinical and
genetically confirmed homozygous
familial hypercholesterolaemia
Historically, the frequencyof clinical HoFHhas been estimated at 1 in
1 000 000 and for heterozygous FH (HeFH) 1 in 500,1 although
higher frequencies in specific populations, such as French Canadians,
Afrikaners in South Africa, or Christian Lebanese, have been
reported due to founder effects.3 However, recent studies in unse-
lected general populations suggest that the prevalence of HeFH
based on the Dutch Lipid Clinic Network criteria may be as high
as 1 in 2004 or, for molecularly defined HeFH, 1 in 244.5 Conse-
quently, HoFH may affect as many as 1 in 160 000–300 000
people (Figure 1).
Genetics of homozygous familial
hypercholesterolaemia
The proteins known to affect LDL receptor function and their role are
summarized in Figure 2.Most patientswith genetically confirmedHoFH
have two mutant alleles of the LDLR gene (MIM 606945) and their
parents each have HeFH. Recently, mutations in alleles of three other
genes were identified as causal in some cases with a severe phenotype
resemblingHoFH.These secondary genes areAPOB (MIM107730) en-
coding apolipoprotein (apo) B, PCSK9 (MIM 607786) encoding pro-
protein convertase subtilisin/kexin type 9 (PCSK9), and LDLRAP1
(MIM 695747) encoding LDL receptor adapter protein 1, which
uniquely causes a recessive phenotype, since carrier parents have
normal lipid profiles.6 Patients are homozygotes, with the same
Figure1 Estimatednumberof individualsworldwidewith homo-
zygous familial hypercholesterolaemia by theWorldHealthOrgan-
ization region. Estimates are based on historical prevalence data
(1 in a million with homozygous familial hypercholesterolaemia),
as well as directly detected estimates of familial hypercholesterol-
aemia in the Danish general population (1/160 000). Data from
Nordestgaard et al.4
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Figure 2 Proteins affecting low-density lipoprotein receptor function. (A) (1) Newly synthesized low-density lipoprotein receptor (LDLR) is
transported to the cell membrane. After reaching the cell surface, the low-density lipoprotein receptor binds apolipoprotein B-100 (apoB-100),
the main protein on LDL, forming a complex. (2) The low-density lipoprotein receptor–low-density lipoprotein complex, located in a clarithin-
coatedpit, is endocytosed via interactions that involve the low-density lipoprotein receptorAdaptorProtein 1 (LDLRAP1). (3) Inside theendosome,
the complex dissociates: apoB-100 and lipids are targeted to the lysosome and degraded, the low-density lipoprotein receptor recycles to the cell
membrane. (4) Pro-protein convertase subtilisin/kexin type 9 (PCSK9) acts as a post-transcriptional low-density lipoprotein receptor inhibitor and
through an interaction with it, targets the low-density lipoprotein receptor for degradation, instead of recycling. (B) In the presence of
loss-of-functionmutations in the gene encoding for the low-density lipoprotein receptor, the low-density lipoprotein receptor is either not synthe-
sized, not transported to the surface, or is present on the surface, but its function is altered. (C) In the presence of mutations in the low-density
lipoprotein receptor-binding region of apoB, its ability to bind to low-density lipoprotein receptor is reduced, with consequent reduction in
low-density lipoprotein particle uptake. (D) In the presenceof gain-of-functionmutations in the geneencoding PCSK9,more low-density lipoprotein
receptors are targeted for degradation, with consequent reduction in the number of low-density lipoprotein receptors which recycle to the cell
surface. (E). In the presence of loss-of-function mutations in the gene encoding for LDLRAP1, which facilitates the interaction between the low-
density lipoprotein receptor and the cell machinery regulating the endocytic process, low-density lipoprotein receptor–low-density lipoprotein
complex internalization is impaired.
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mutation in both alleles of the same gene, or more commonly, com-
pound heterozygotes with different mutations in each allele of the
same gene, or double heterozygotes with mutations in two different
genes affecting LDL receptor function (Figure 3).
Genetic heterogeneity translates
to phenotypic variability
Irrespective of the underlying genetic defect, the severity of the
HoFH phenotype depends on residual LDL receptor activity. Based
on in vitro assays in their cultured fibroblasts, patients with clinically
definedHoFHhavebeenconventionally classified as either receptor-
negative (,2% residual activity) or receptor-defective (2–25%
residual activity).1 Homozygous familial hypercholesterolaemia
patients who are LDLR-negative have higher LDL-C levels and
poorer clinical prognosis than LDLR-defective patients.2,7,8
Residual LDL receptor activity has not been systematically evalu-
ated in patients carrying mutations in APOB and PCSK9 genes. In
patients carrying LDLRAP1 mutations, LDL receptor activity in fibro-
blast culture is normal, although the cause remains unclear.6 Never-
theless, emerging data suggest that carriers of mutations in these
genes may present a milder phenotype compared with that of
receptor-negative subjects.6Overall, mean LDL-C levels by genotype
generally increase as follows: HeFH,double heterozygote (e.g.
LDLR+PCSK9 gain-of-function or APOB mutation) ,homozygous
APOB or PCSK9 gain-of-function mutation ,homozygous LDLRAP1
or LDLR-defective mutations ,compound heterozygote LDLR-
defective+LDLR-negative mutations ,homozygous LDLR-negative
mutations (see Supplementary material online and Figure 4).
Other sources of variability in the HoFH phenotype may arise
from small effect genetic variants (common single nucleotide
polymorphisms), gene–gene and gene–environment interac-
tions, and non-Mendelian and epigenetic influences.6,9,10 Greater
access andwider clinical application of next generation sequencing
are critical to defining such variability, as well as additional causa-
tive genes, all of which have important prognostic and therapeutic
implications.
Metabolic characteristics of
homozygous familial
hypercholesterolaemia
Impaired functionality of the LDL receptor underlies the hyperchol-
esterolaemia of HoFH. While defective hepatic LDL uptake is the
main and most direct consequence, other metabolic perturbations
may contribute to the metabolic characteristics and accelerated ath-
erosclerotic disease associated with HoFH. ApoB metabolism in
HoFH remains incompletely defined, although in vitro and in vivo
studies suggest that LDLR-negative mutations are associated with
hepatic oversecretion of apoB. In addition, while levels of triglycer-
ides are frequently within the normal range, hypertriglyceridaemia
has been observed, and may be more common with an increasing
prevalence of the metabolic syndrome. Decreased catabolism of
triglyceride-rich lipoproteinsmay result fromdeficient LDL receptor
function and account for postprandial dyslipidaemia. Familial hyper-
cholesterolaemia is also associated with increased plasma levels of
lipoprotein(a) [Lp(a)] by an undefined mechanism that may not dir-
ectly involve the LDL receptor pathway. Lipoprotein(a) levels tend
tobehigher inHoFHthanHeFH, and are independentof genetic vari-
ation in apolipoprotein(a).4 Finally, HoFH patients frequently have
low levels of high-density lipoprotein cholesterol (HDL-C), probably
due to accelerated turnover of HDL apoA-I, and defective
HDL-driven cholesterol efflux. These metabolic perturbations
have been extensively reviewed.11
Figure 3 Genetics and genetic heterogeneity of homozygous fa-
milial hypercholesterolaemia. (A) Inheritance of homozygous famil-
ial hypercholesterolaemia in a pedigree. In a mating between
heterozygous parents who each carry one copy of a familial
hypercholesterolaemia-mutation-bearing allele, 25% of children
will carry two copies of wild-type alleles (homozygous normal);
50%will be heterozygotes; and 25%will carry two copies of familial
hypercholesterolaemia-mutation-bearing alleles (homozygous fa-
milial hypercholesterolaemia). The particular genes and mutation
types inherited determine whether the affected individual is a
simple homozygote, or compound or double heterozygote. (B)
Genetic heterogeneity of familial hypercholesterolaemia. Ideo-
grams for chromosomes 1, 2, and 19 indicate the positions of the
four main familial hypercholesterolaemia-causing genes, which in
the descending order of frequency are LDLR (.95%), APOB (2–
5%), PCSK9 (,1%), and LDLRAP1 (,1%). For the vast majority of
homozygous familial hypercholesterolaemia patients represented
in (A), mutation-causing alleles are within the same gene (usually
LDLR) and patients are referred to as ‘true homozygotes’. Homozy-
gous familial hypercholesterolaemia patients who carry the same
mutation on each allele are called ‘simple homozygotes’, while
those who inherit different mutations from within the same gene
are called ‘compound heterozygotes’. Finally, very rare homozy-
gous familial hypercholesterolaemia patients have familial hyper-
cholesterolaemia mutation-bearing alleles from two different
familial hypercholesterolaemia loci: the first is almost always
within the LDLR, while the second is from one of the other three
loci. Such patients are called ‘double heterozygotes’.
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Diagnosis of homozygous familial
hypercholesterolaemia
Diagnosis of HoFH can bemade on the basis of genetic or clinical cri-
teria (Box 1).While genetic testingmay provide a definitive diagnosis
of HoFH, it is recognized that in some patients genetic confirmation
remains elusive, despite exhaustive investigation; indeed, the exist-
ence of additional FH genes cannot be excluded.4 Historically,
HoFHhasbeenmost commonlydiagnosedon thebasisof anuntreat-
ed LDL-C plasma concentration .13 mmol/L (.500 mg/dL), or a
treated LDL-C concentration of ≥8 mmol/L (≥300 mg/dL), and
the presence of cutaneous or tendon xanthomas before the age of
10 years, or the presenceof untreatedelevated LDL-C levels consist-
ent with HeFH in both parents.
Plasma low-density lipoprotein
cholesterol levels
Within a family, the plasma LDL-C level is the critical discriminator,
being about four times and about two times higher in family
members with HoFH or HeFH, respectively, compared with un-
affected members.6 At the population level, however, the range of
LDL-C levels may overlap significantly between HeFH and HoFH
(Figure 4), and untreated LDL-C levels ,13 mmol/L (,500 mg/dL)
can be found in genetically confirmedHoFH.5,8 This is especially rele-
vant for children, who tend to have lower LDL-C levels than adults.
More than 50% of HoFH children identified in the Netherlands
have LDL-C levels between 5.6 and 9.8 mmol/L (AWiegman personal
communication). Such phenotypic heterogeneity can be at least partly
explained by the previously described genotypic heterogeneity.
Thus, the LDL-C cut-offs given here should not be the sole guide
for diagnosis. Indeed, the treated LDL-C cut-off of .8 mmol/L
(.300 mg/dL) is now considered obsolete, given the multiplicity of
lipid-lowering treatments that these patients typically receive. This
point is clearly illustrated in a recent trial, in which HoFH patients
with a confirmed genetic diagnosis had baseline LDL-C levels as
low as 3.9 mmol/L (150 mg/dL) while onmultiple LDL-C lowering
agents,12 as well as in a recent report.5
Xanthomas and arcus corneae
Although not exclusively associated with HoFH, the presence of cu-
taneous or tuberous xanthomas in children is highly suggestive of
diagnosis (Figure 5). Evidence of arcus corneae reinforces the clinical
diagnosis. As seen for LDL-C levels, variability in the age at appear-
ance and extension of xanthomas can be partly explained by the
underlying mutations, with earlier appearance of xanthomas asso-
ciated with receptor-negative vs. receptor-defective status.2,8 Chol-
esterol deposits in the tendons and joints may lead to tendinitis and
joint pain, which impairs the quality of life of patients, and these may
Box1 Criteria for the diagnosis of homozygous familial
hypercholesterolaemia
† Genetic confirmationof twomutant alleles at the LDLR,APOB, PCSK9,
or LDLRAP1 gene locus
OR
† An untreated LDL-C .13 mmol/L (500 mg/dL) or treated LDL-C
≥8 mmol/L (300 mg/dL)* together with either:
W Cutaneous or tendon xanthoma before age 10 years
or
WUntreated elevated LDL-C levels consistent with heterozygous FH in
both parents
* These LDL-C levels are only indicative, and lower levels, especially in
children or in treated patients, do not exclude HoFH
Figure4 Phenotypic variability in homozygous familial hypercholesterolaemia. For full explanation and relevant literature refer to Supplementary
material online. LDL, low-density lipoprotein; APOB, apolipoprotein B; PCSK9, pro-protein convertase subtilisin/kexin type 9; LDLRAP1, LDL re-
ceptor adaptor protein 1 (i.e. ARH, autosomal recessive hypercholesterolaemia).
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require surgical removal. In rare cases, patients may present with
giant ectopic cholesterol xanthomas in the brain, mediastinum, and
muscles of the buttock.13 As referral following the appearance of
xanthomas in young children is frequently the key driver of HoFH
diagnosis,2,14–16 prompt recognition is crucial to early diagnosis.
The presence of markedly elevated LDL-C levels and the absence
of neurological, cognitive, and ophthalmic symptoms in patients
with HoFH distinguish them from patients with cerebrotendinous
xanthomatosis.17
Family history
A careful family history is essential for comprehensive assessment of
possible FH in general, and HoFH in particular.4 In the case of auto-
somal dominant mutations (in LDLR, PCSK9, and APOB genes), both
parents are obligate heterozygotes and therefore display elevated
LDL-C levels (frequently .95th percentile by country-specific age
and gender criteria) and a strong positive family history of premature
ACVD (,55 years in men and ,60 years in women among first-
degree relatives). In the case of autosomal recessive hypercholester-
olaemia (due to LDLRAP1 mutations), parents may exhibit LDL-C
levels in the normal range, and determination of an extended family
pedigree may reveal an autosomal recessive pattern of inheritance.
Systematic cascade or opportunistic screening offers prospective
parents with HeFH the possibility of making informed decisions pre-
natally, and identifying HoFH patients at birth, thereby allowing for
early initiation of treatment. Identification of HoFH can also guide
‘reverse’ cascade screening for parents and relatives to identify
patients with FH.
Differentiation from sitosterolaemia
Although in most cases the diagnosis of HoFH is relatively straight-
forward, another disorder of lipid metabolism, sitosterolaemia
(alternatively termed ‘phytosterolaemia’), may have a very similar
clinical presentation, with the presence of tendinous and/or tuber-
ous xanthomas in childhood associated with a dramatic increase
in plasma cholesterol and atherosclerotic complications.18 It is,
however, of relevance that atherosclerotic disease is not always
present in genetically defined sitosterolaemic subjects, as shown
in a recent report.19 Similar to autosomal recessive hypercholester-
olaemia, sitosterolaemia has an autosomal recessive pattern of
inheritance and consequently parents may present with normal
cholesterol levels. Two major features differentiate sitosterolaemia
from HoFH: (i) markedly (.30-fold) increased plasma concentra-
tions of plant sterols,18 and (ii) elevated cholesterol levels, which
respond well to diet and bile acid sequestrants or ezetimibe and
may not persist after the first two decades of life.18,19 Diagnosis is
confirmed by genetic analysis, with mutations in two ATP binding
cassette transporter genes, ABCG5 and/or ABCG8, shown to be
causative for sitosterolaemia.18
In summary, this Consensus Panel recommends that diagnosis is
made by careful assessment of the clinical characteristics and family
history, as well as genetic testing when the clinical diagnosis of
HoFH is uncertain or to facilitate ‘reverse’ cascade screening.
‘Reverse’ cascade screening is in any case strongly recommended.
Cardiovascular complications and
natural history
The burden of markedly elevated plasma LDL-C levels from birth
underlies the sequelae of ACVD complications unique to HoFH.4
The cholesterol-year score, an integrated measure of the severity
and the duration of hypercholesterolaemia, is directly associated
with cholesterol deposition in vascular and extravascular compart-
ments inHoFHpatients,20 thus reinforcing the concept that absolute
LDL-C levels affect the severity of the CV phenotype. In clinically
diagnosed HoFH, the first major CV events often occur during ado-
lescence,2,21,22 although angina pectoris, myocardial infarction and
death have been reported in early childhood, typically in individuals
who are LDLR-negative.1,2,14–16,21 Untreated HoFH patients who
are LDLR-negative rarely survive beyond the second decade. While
HoFH patients who are LDLR-defective have a better prognosis,
almost all develop clinically significant ACVDby age of 30. Long-term
studies are still needed to assess CV risk in genetically confirmed
HoFH without the severe phenotype usually observed in clinically
defined HoFH.
Homozygous familial hypercholesterolaemia is characterized by
accelerated atherosclerosis, typically affecting the aortic root, com-
promising the coronary ostia, but also other territories, including
the carotid, descending aorta, and ileo-femoral and renal arteries.1,23
Cholesterol and calciumdeposits, aswell as fibrosis and inflammation
in both the aortic root and aortic valve cusps, can lead to supra-
valvular aortic stenosis (Figure 6).1,24 These manifestations often
occur within the first and second decades of life.1,2,21,23 Patients
may be initially asymptomatic, presenting only with cutaneous and
tendinous xanthomas and possibly, a cardiac murmur in the aortic
area.2,25 Early involvement of the ascending and descending thoracic
aorta is frequently observed,1 accompanied by premature severe
aortic calcification in adult patients.26 Cholesterol deposition on
valve leaflets may also cause mitral regurgitation.1
Importantly, valvular and supra-valvular aortic diseases may pro-
gress evenwhen cholesterol levels are reduced, as a result of haemo-
dynamic stress and progressive fibrosis over affected territories.24
Dyspnoea, diastolic and systolic left ventricle heart failure, and
sudden cardiac death are also common.1,23 In young children, the
Figure5 Cutaneous and tuberousxanthomas in homozygous fa-
milial hypercholesterolaemia. Interdigital xanthomas (see B, yellow
arrows) in children are highly suggestive of homozygous familial
hypercholesterolaemia diagnosis. Photograph (A) kindly provided
by Prof. Eric Bruckert. Photograph (B) kindly supplied by Prof. Fred-
erick Raal.
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first symptoms and signs are frequently linked to aortic stenosis and
regurgitation.2 Angina pectoris, resulting from both reduced oxygen
supply caused by coronary atherosclerosis and increased left ven-
tricular demand consequent to left ventricle hypertrophy and left
ventricular outflow obstruction, can occur at any age, depending
on the rate of progression and severity of phenotype (Box 2).
Screening for subclinical atherosclerosis
Given the extremely high risk of early onset of severe ACVD and its
rapid progression in HoFH, regular screening for subclinical aortic
and coronary heart disease (CHD) is indicated. This Consensus
Panel recommends that patients receive a comprehensive CV
evaluation at diagnosis, with subsequent Doppler echocardiographic
evaluation of the heart and aorta annually, and, if available, computed
tomography coronary angiography (CTCA) every 5 years, or more
frequently if clinically indicated, taking into account the radiation ex-
posure and severity of subclinical disease. Computed tomography
coronary angiography can detect luminal obstruction by calcified
and non-calcified plaques27 and results can be combined with
those from myocardial stress testing, provided the age of the child
permits consent. Stress testing, although not optimal for detecting
subclinical disease, may be used in case of limited access to CTCA
or cardiac magnetic resonance imaging (MRI). Owing to concerns
about the exposure of young individuals to radiation, CTCA must
be performed in CT scanners with at least 64 and preferably 320
detectors or dual source scanners, with radiation exposure adapted
for body weight.28 The atherosclerotic burden of the aorta can be
also evaluated by MRI29 or trans-oesophageal echocardiography.30
Stress testing and invasive coronary angiography are indicated in
patients with clinical symptoms suggestive of ischaemia or valve mal-
function, or in the presence of findings from non-invasive cardiac
evaluation. Given the high rate of ostial stenosis, risk of sudden
death and inability to undertake stress testing due to age, invasive
angiography may be indicated in severely affected young children.
This should be performed by an experienced paediatric invasive
cardiologist. Coronary revascularization is indicated for severe
CHD, and aortic valve replacement for severe left ventricle
outflow obstruction. For either surgery, care must be taken with
the aortic root as it is usually severely compromised by atheroscler-
otic plaques andcalcification. Reconstructionof the aortic rootmight
be necessary with aortic valve replacement.31 These patients
should be followed by a team of experts including a lipidologist
and cardiologist working in close collaboration to optimize thera-
peutic measures, including pharmacological antiplatelet treatment,
prevention of endocarditis especially in those with valve prosthesis
or aortic grafts, and surgical intervention to correct valvular and cor-
onary impairment.
Current treatment for
homozygous familial
hypercholesterolaemia
Given the ACVD complications associated with HoFH, reducing the
burden of elevated LDL-C levels is critical. A low-saturated fat, low-
cholesterol, heart-healthy diet should be encouraged in all patients
with HoFH, but even with strict adherence, diet has little impact on
the severity of hypercholesterolaemia. Patients should be encour-
aged to be active. As aortic stenosis may precipitate angina and
syncope on exertion, a careful assessment of the aortic and ostial in-
volvement is recommended before sport activities are initiated.
While other risk factors such as smoking, hypertension, and diabetes
should be aggressively targeted, and aspirin is of value in asymptom-
atic patients, the most important aim of therapy is to reduce LDL-C
levels as much as possible.
Pharmacotherapy
This Consensus Panel strongly recommends that lipid-lowering
therapy should be started as early as possible, based on evidence
that treatment can delay the onset of clinically evident ACVD.2,21
In accordance with recently published guidelines,4 LDL-C targets in
HoFH are ,2.5 mmol/L (,100 mg/dL) [,3.5 mmol/L (,135 mg/dL)
Box 2 Cardiovascular complications of homozygous
familial hypercholesterolaemia
† HoFH is characterized by accelerated atherosclerosis, typically
affecting the aortic root, although other vascular territories may also
be affected.
† The first major cardiovascular events often occur during
adolescence, possibly younger when patients are LDLR-negative and/
or untreated.
† In young children, early symptoms and signs are often linked to aortic
stenosis and regurgitation, due to massive accumulation of
cholesterol at the valvular levels.
† As aortic and supra-valvular aortic valve diseases may progress even
when cholesterol levels are reduced, regular screening for subclinical
aortic, carotid, and coronary heart disease is indicated.
Figure 6 Postero-lateral view of computed tomography angiog-
raphy of a homozygous familial hypercholesterolaemia patient. The
arrows indicate (1) calcified (in white) and non-calcified (in yellow)
atherosclerotic plaques in the supra-aortic valve region; (2) calcified
plaques on the aortic valve region (depicted in green); (3) calcified
and non-calcified plaques in the ascending aorta; and (4 and 5) cal-
cified, non-calcified andmixed plaques in themiddle and distal right
coronary artery. Image kindly provided by Prof. Raul D. Santos.
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in children], or ,1.8 mmol/L (,70 mg/dL) in adults with clinical
ACVD. However, such targets are ambitious and careful evaluation
of the benefit vs. risk of therapeutic options is needed. The Panel
also recognizes that the genetic and phenotypic heterogeneity of
HoFH may translate to broad variability in the response to conven-
tional and novel lipid-lowering therapies.
Statins have proven efficacy as themainstay of treatment in HoFH,
even in individuals who are receptor-negative,32–36 and have been
shown to reduce CV and all-cause mortality.21 Even at the highest
doses of the most efficacious statins, however, only modest reduc-
tions in LDL-C plasma levels, of 10–25%, are observed in most
patients. Autosomal recessive hypercholesterolaemia seems rela-
tively more responsive to treatment.37 Addition of the cholesterol
absorption inhibitor ezetimibe further lowers LDL-C levels by
10–15%,38 thus providing 30–40% reduction in LDL-C levels, with
minimal adverse events and relative low costs (Figure 7). Combina-
tions of statins with other cholesterol-lowering medications, includ-
ing bile acid sequestrants, niacin, fibrates, and probucol have been
used successfully in HoFH and can be considered to further lower
LDL-C levels, although their use may be limited by tolerability and
availability.
Lipoprotein apheresis
Where available, extracorporeal removal of LDL-C, although an ex-
pensive and time-consuming therapeutic approach, is an important
adjunctive treatment forHoFH.39–42The initial unselective approach
of plasma exchange (plasmapheresis) has been replaced by several
methods for selective elimination of atherogenic lipoproteins.43 A
single treatment can decrease plasma LDL-C levels by 55–70% rela-
tive to pre-treatment levels, with close to normal LDL-C levels
achievedwith apheresis on aonceweekly basis. Long-term treatment
frequently results in regression of cutaneous xanthomas (Figure 8).
Side effects of apheresis include hypotension, abdominal pain,
nausea, hypocalcaemia, iron-deficiency anaemia, and allergic reac-
tions. These are rarely serious but can be debilitating. Depending
on the technique used, particularly with dextran sulphate LDL ab-
sorption and haemoperfusion methods, concomitant therapy with
an angiotensin-converting enzyme inhibitor is contraindicated due
to the risk of severe hypotension.44
Despite the lack of randomized studies, there is clinical evidence
that long-term lipoprotein apheresis can contribute to plaque regres-
sion and/or stabilization and improve prognosis, as extensively
reviewed,43 and is cost-effective in HoFH, especially in severe pheno-
types (see Supplementarymaterial online).Whetherother effects, in-
cluding marked reduction in Lp(a),42 add benefit to the CV prognosis
remains to be established.Accumulatingdata strongly suggest that the
earlier apheresis is initiated, the better the prognosis. In practice, the
age of starting and the frequency of treatment represent a comprom-
ise between practical feasibility, cost and the clinical need to achieve
LDL-C target. In very young patients (2 years),45,46 venous access
can be an issue, although this can be achieved with a peripheral
venous cannula. While the theoretical optimal frequency is one pro-
cedure perweek,most centres treat patients every 2weeks. Lipopro-
tein apheresis can be continued during pregnancy.40,42
In line with current guidelines,39–41 this Consensus Panel recom-
mends that lipoprotein apheresis be considered in patients with
HoFH. Treatment should be started as soon as possible, ideally by
Figure 7 Cumulative low-density lipoprotein cholesterol-
lowering effects of statin, ezetimibe, adjunctive mipomersen, lomi-
tapide or evolocumab, and lipoprotein apheresis in homozygous
familial hypercholesterolaemia. The per cent low-density lipopro-
tein cholesterol reduction is dependent on baseline low-density
lipoprotein cholesterol values. *The figure illustrates the decrease
in low-density lipoprotein cholesterol after a single apheresis treat-
ment. The low-density lipoprotein cholesterol level achieved after
treatment is higher in patients with higher baseline value. However,
the rebound curves after treatment are more or less parallel. See
Schuff-Werner et al.43
Figure8 Case study showingbefore (A) and4 years after starting
weekly lipoprotein apheresis (B) in a homozygous familial hyper-
cholesterolaemia patient carrying a non-sense mutation in the
ARH gene. The patient presented in early childhood with extensive
xanthomas on the knees (right knee shown), elbows, buttocks and
the Achilles tendon, and elevated total and low-density lipoprotein
cholesterol levels [21.9 mmol/L or 850 mg/dL; lipoprotein(a)
75 mg/dL]. After 4 years on treatment (statin, ezetimibe plus lipo-
protein apheresis), there was total regression of the xanthomas
of the knees, buttocks, and elbows. Low-density lipoprotein choles-
terol levels at last report were 5.7 mmol/L (220 mg/dL) and
1.8 mmol/L (70 mg/dL) before and after apheresis; lipoprotein(a)
levels were 50 and 16 mg/dL, respectively. Photographs kindly pro-
vided by Prof. Elisabeth Steinhagen-Thiessen.
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age 5 and not later than 8 years, although this and the frequency of
treatment represent a compromise between access to centres, the
severity of the disease, affordability, and the patient’s choice.
Liver transplantation and other surgical
approaches
Liver transplantation corrects themolecular defect in theorganmost
active in the clearance of LDL, resulting in a marked improvement of
LDL-C levels.1 Although a successful therapeutic strategy, either
alone or in combination with a heart transplant,47–49 there are
obvious disadvantages, including the high risk of post-transplantation
surgical complications and mortality, the paucity of donors, and the
need for life-long treatment with immunosuppressive therapy.50
Partial ileal bypass or portocaval shunting is not recommended, but
may be considered where there is limited access to more efficacious
treatments for patients with very severe phenotypes.
In conclusion, this Consensus Panel emphasizes the need for a
combination of lifestyle, statin treatment (with or without other
lipid-lowering drugs) and lipoprotein apheresis to manage HoFH.
While this approachmaybe sufficient to attain LDL-C goal in patients
with a ‘milder’ phenotype, the Panel recognizes thatHoFH is typically
refractory toexisting lipid-lowering therapies and that there areprac-
tical limitations with apheresis. Novel lipid-lowering agents with dif-
ferent mechanisms of action might improve the management of
this condition (Figure 9).
New therapeutic approaches
affecting low-density lipoprotein
production
Lomitapide and mipomersen were recently approved by the Food
and Drug Administration (FDA) as adjunct therapy for HoFH in
patients aged ≥18 and ≥12 years, respectively; lomitapide is also
approvedby the EuropeanMedicinesAgency. Although targeting dif-
ferent proteins via different strategies, both drugs affect the produc-
tion and secretion of apoB-containing lipoproteins,51,52 rather than
increasing their removal from circulation. As HoFH is characterized
by severely impaired removal of LDL from the bloodstream, these
new agents represent a promising approach for treatment of hyper-
cholesterolaemia.
Lomitapide
Lomitapide is an oral inhibitor of the microsomal triglyceride trans-
port protein (MTP),which is responsible for transferring triglycerides
andphospholipidsontochylomicronandVLDLduring their assembly
in the intestine and the liver, respectively.53 Inhibiting MTP leads to
reduced secretion of these lipoproteins into the circulation. In an
open-label trial in HoFH patients, lomitapide at maximally tolerated
doses, in addition to the standard of care including LDL apheresis,
reduced plasma LDL-C and apoB levels by 50% and Lp(a) by
15% at 26 weeks, with durable LDL-C lowering over a further 12
Figure9 Novel lipid-regulating drug targets. Novel drugs target either very low-density lipoprotein production (VLDL), by inhibiting apolipopro-
teinB synthesis (apolipoproteinB [apoB] antisenseoligonucleotide,mipomersen)or lipid loadingontonascent apoB [microsomal triglyceride trans-
fer protein (MTP) inhibitor, lomitapide], or low-density lipoprotein catabolism by increasing low-density lipoprotein receptor recycling (PCSK9
inhibitors).
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months follow-up.12 The most frequently observed adverse events
were gastrointestinal symptoms and liver fat accumulation. Gastro-
intestinal adverse events (e.g. nausea, flatulence, and diarrhoea)
were reduced by a gradual dose-escalation regimen combined with
adherence to a low-fat diet (,20% of energy from fat) and dosing
outside of mealtimes.12 Elevations in alanine aminotransaminase
(ALT) .3 × upper limit of normal (ULN) were reported for 10
patients (34%).12 Accumulation of liver fat up to a median level of
9% (range 0–34%) at 26 weeks and 8% (0–19%) at 78 weeks was
observed.12
Mipomersen
Mipomersen is a second generation antisense oligonucleotide, admi-
nistered by subcutaneous injection, that targets the messenger ribo-
nucleic acid (mRNA) of apoB, the main protein of LDL, and its
precursor, VLDL. Mipomersen reduces translation of apoB mRNA
and the synthesis of apoB by the ribosome, leading to reduced
secretion of VLDL.51 In a placebo-controlled double-blind trial in
HoFH patients, mipomersen (weekly 200 mg, on top of standard
lipid-lowering therapy), resulted in further reductions from baseline
at 26 weeks in plasma levels of LDL-C (mean 25%), apoB (27%), and
Lp(a) (31%) vs. placebo.54 The most frequently reported adverse
events were injection site reactions (76% of patients), some of
which were long-lasting, and flu-like symptoms, typically appearing
2 days after injection.54 Elevations in ALT have been reported
during mipomersen treatment; in 12% of patients, increases .3 ×
ULN, with or without concomitant increases in liver fat content,
were observed although most subsequently decreased while con-
tinuing treatment.54 Liver fat content was not routinely measured
in the HoFH study with mipomersen, although in hypercholestero-
laemic patients, including those with HeFH, a median increase of
5% (range 21 to 37%) after 28 weeks treatment was observed.55
Increased liver fat content observed during both lomitapide and
mipomersen treatment may be correlated with the degree of effi-
cacy.12,54 The limited available data suggest that this effect is revers-
ible following suspension of treatment. Owing to the potential risk
for hepatic toxicity, both agents have been approved for restricted
use. Although the potential CV benefits associated with substantial
LDL-C lowering possibly outweigh the theoretical increased risk of
steatohepatitis and fibrosis in such very high-risk patients, a system-
atic evaluation of long-term efficacy, outcome and hepatic safety is
clearly necessary. Additionally, both drugs have adverse events that
may limit long-term use. Lomitapide is also contraindicated with
strong andmoderateCYP3A4 inhibitors. Furthermore, as lomitapide
has not been evaluated in HoFH patients aged,18 years, and mipo-
mersen in those,12 years or receiving apheresis, treatment in such
patients should only be considered via a special access scheme in the
event of rapidly progressive atherosclerosis and if other options have
been utilized.
Undoubtedly, statins and other conventional lipid-lowering drugs
are availableworldwide and affordable, comparedwith apheresis and
recent therapeutic options. Although the high costs of these
approaches may be a concern, the overall cost to adequately treat
HoFH remains low due to its rarity and may be counterbalanced by
the cost of treating associated CV complications.
Future options
A number of novel agents may also offer therapeutic options for
HoFH. Monoclonal antibody therapies targeting PCSK9 are being
developed (Figure 9). In HeFH patients, this therapy reduced
plasma LDL-C levels by up to 65% on top of concomitant
lipid-lowering therapy.56,57 Subsequently, a proof of concept study
showed that evolocumab (AMG 145, 420 mg subcutaneously
every 2 weeks), reduced plasma LDL-C levels by 26% (mean
3.0 mmol/L) in HoFH patients who were receptor defective58; in a
placebo-controlled phase 3 trial evolocumab reduced LDL-C
levels by 31%.59Given thatmarkedly elevatedPCSK9 levels are asso-
ciated withHoFH, either untreated or treatedwith statins,60 the use
of PCSK9 inhibitors as adjunct therapy in subjects with LDLR defect-
ive mutations or PCSK9 gain-of-function mutations offers an add-
itional therapeutic approach to optimizing LDL-C reduction.
Moreover, inhibitors of cholesteryl ester transfer protein (CETP)
have been shown to significantly lower LDL-C and Lp(a) levels by in-
creasing the clearance of apoB-containing lipoproteins.61 Prelimin-
ary findings suggest that combination with a statin may be effective
in HoFH.62
Finally, rapid resolution of severe hypercholesterolaemia fol-
lowing liver transplantation in HoFH provides compelling
support for the hypothesis that liver expression of LDLR via gene
replacement may not only decrease LDL-C levels, but also make
HoFH patients more responsive to existing or novel therapeutics.
Indeed, early attempts investigating gene replacement therapy
resulted in a transitory expression of the LDLR in some HoFH
patients.63 Recent successes in humanized mouse models of
HoFH using an AAV8-based gene therapy approach support
further development.64
Other issues
In addition to pharmacological treatment of hypercholesterol-
aemia, management of the HoFH patient should address other
issues (Box 3). Diagnosis of HeFH can impact psychosocial
functioning and quality of life, even more so for HoFH patients,
implying the need for integration of psychological support into
routine patient care.65 Thus, this Panel recommends that parents
and children should be appropriately educated about HoFH,
thereby providing a basis for shared decision-making regarding
their treatment.
Contraception and pregnancy should be appropriately discussed
for female patients; as hormonal control is generally contraindicated
in HoFH, other contraceptive methods are strongly recommended
(Box 3). The consequences of pregnancy, i.e. aggravation of hyper-
cholesterolaemia due to discontinuation of pharmacotherapy,
coupledwith the effects of high levels of oestrogen andprogesterone
on lipoprotein metabolism,66,67 also merit consideration. In the
absence of appropriate studies and on the basis of current experi-
ence, thisConsensusPanel recommends a full discussion anddetailed
CV assessment in women who wish to become pregnant. Where
pregnancy is not contraindicated, lipoprotein apheresis is strongly
recommended.
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Consensus panel
recommendations
Recommendations of this Consensus Panel are summarized in Box 3.
Early diagnosis of HoFH and early initiation of lipid-lowering therapy
are paramount.While genetic testing can usually provide a definitive
diagnosis of HoFH, clinicians should be aware that in some patients,
genetic confirmation remains elusive.4 Plasma levels of LDL-C should
not be the sole criterion for diagnosis given emerging evidence that
the genetic heterogeneity of HoFH translates to phenotypic variabil-
ity to a greater level than previously thought.
Current management of HoFH should focus on lifestyle interven-
tion, togetherwithmaximal statin therapy, often in combinationwith
ezetimibe and other lipid-modifying therapy, and adjunctive lipopro-
tein apheresis (Figure 10), consistent with recent guidance.4,68
Despite this multiplicity of treatments, it is recognized that most
patients with HoFH do not achieve recommended LDL-C targets
and therefore remain at high CV risk. For these patients, the recent
approval of lomitapide andmipomersen as adjunctive therapy specif-
ically forHoFH, considered togetherwith the potential of newCETP
inhibitors andPCSK9 immunotherapy,offers thepossibilityof further
LDL-C lowering on top of current standards of care. Subject to con-
sideration of benefit vs. risk and cost, which may differ from country
to country, such pharmacotherapies may ultimately translate to
improved clinical outcome for patientswith this rare, life-threatening
genetic disease.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Figure 10 Suggested algorithm formanagement of homozygous
familial hypercholesterolaemia.
Box 3 Summary of EAS Consensus Panel
recommendations
† Diagnosis; refer to Box 1 for diagnostic criteria
– Patients with suspected diagnosis should be referred to a
specialized centre for proper comprehensive management
– Genetic analysis should be considered to
W Confirm the clinical diagnosis
W Facilitate testing of familymembers (reverse cascade screening)
W Assist in diagnosis where clinical presentation is borderline
between that of HoFH and heterozygous FH
† Screening for subclinical ACVD
Patients should undergo comprehensive CV evaluation at diagnosis,
with subsequent Doppler echocardiographic evaluation of the heart
and aorta annually, stress testing and, if available, computed
tomography coronary angiography every 5 years or more frequently
if needed.
† Management
– Current management of HoFH focuses on a combination of
lifestyle, statin treatment (with or without ezetimibe) and
lipoprotein apheresis if available.
– Lipid-lowering therapy should be started as early as possible.
– Lipoprotein apheresis should be considered in all patients with
HoFH, and startedas soonaspossible, ideally byage5andnot later
than 8 years.
– Lomitapide and mipomersen should be considered as adjunctive
treatments to further lower plasma LDL-C levels in patients with
HoFH.
† Other issues
– Contraception andpregnancyare key issues in female patients and
should be appropriately discussed. Hormonal contraception is
generally contraindicated in HoFH, and other contraceptive
methods are strongly preferred. Women wishing to become
pregnant should be counselled and undergo detailed CV
assessment. Where pregnancy is not contraindicated, women
should remain on LDL apheresis.
– Psychological support should be integrated into routine care.
Patient and family support groups clearly have a role.
– Surgery may be considered to remove large cutaneous or
tuberous xanthomas for either functional or cosmetic reasons
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